美迪西请回答为您讲解GLP-1 受体激动剂的发展。

胰高血糖素样肽-1（GLP-1）受体激动剂布局最多的适应症为2型糖尿病和肥胖症。

GLP-1 receptor agonists are now used for the treatment of type 2 diabetes and obesity.

回顾从前，从发现GLP-1是胰高血糖素原经酶促裂解后发生的，再到Exendent-4 的发现。

Looking back, GLP-1 was found to be a cleavage product of proglucagon processing.

Exendent-4 是GLP-1发展史上的一个关键的突破。Exendent-4是一种对GLP-1受体具有激动作用但能抵抗DPP-4降解的肽。司美格鲁肽是全球首款口服的GLP-1受体激动剂。

A key breakthrough came from the discovery of exendent-4. Exendent-4 is a peptide with agonistic properties at the GLP-1 receptor but resistance to degradation by DPP-4.Semiglutide, the first oral GLP-1 receptor agonist marked the next milestone.

美迪西“GLP-1”新药研发服务平台

美迪西内分泌及代谢性疾病模型